Definium Therapeutics (DFTX) Cash & Current Investments (2020 - 2026)

Definium Therapeutics (DFTX) has 6 years of Cash & Current Investments data on file, last reported at $368.1 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $368.1 million, up 75.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $368.1 million (up 75.3% YoY), and the FY2025 annual result was $409.1 million, up 50.67% from the prior year.
• Cash & Current Investments eased to $368.1 million in Q1 2026 per DFTX's latest filing, from $409.1 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $409.1 million in Q4 2025 and troughed at $99.7 million in Q4 2023.
• A 5-year average of $204.8 million and a median of $196.0 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments soared 172.31% in 2024, then fell 29.2% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $131.7 million in 2022, then decreased by 24.29% to $99.7 million in 2023, then soared by 172.31% to $271.5 million in 2024, then surged by 50.67% to $409.1 million in 2025, then slipped by 10.01% to $368.1 million in 2026.
• Business Quant data shows DFTX's Cash & Current Investments at $368.1 million in Q1 2026, $409.1 million in Q4 2025, and $209.1 million in Q3 2025.